Drug Trial Radar · NCT03587766
Oral Fexinidazole Dosing Regimens for the Treatment of Adults With Chronic Indeterminate Chagas Disease
Last checked: Nov 20, 2026Latest source record: Sep 23, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
45
Actual
Start
Nov 13, 2017
Primary completion
Dec 19, 2018
Study completion Aug 28, 2019
Sponsor
- Lead sponsor
- Drugs for Neglected DiseasesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 16, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study focuses on the evaluation of low doses (600 and 1200 mg) and short treatment duration (at 3, 7 and 10 days) of fexinidazole (Fexi) to determine the minimal efficacious and safe dose for the treatment of adult patients with chronic indeterminate Chagas Disease (CD).
Conditions
- Chagas' Disease (Chronic) Nos
Interventions
FexinidazoleDrug
Drug: fexinidazole (FEXI)
Placebo Oral TabletDrug
Drug: fexinidazole
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse events.Time frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hospital Clinic
Barcelona, Catalunia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.